CDT Equity Inc. Warrant (CDTTW)
Stock · NASDAQ · Health Care
$0.0074as of 10/16/2026
Price chart
Active signals
High Beta88.3%
Volume Spike50.0%Resistance level
$0.009769
Industry
Biotechnology: Pharmaceutical Preparations
About CDTTW
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diab…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 4
Fundamentals
- 1-day range
- $0.0051$0.0074
- Market cap
- $9.3K
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- —
- Dividend yield
- —
- Beta
- 2.99
- Avg. volume
- —
52-week range
$0.002$0.02
CDT Equity Inc. Warrant Competitors
Chosen by industry and closest market cap.
- CDTTWCDT Equity Inc. Warrant$0.0074▲ 21.31%Market cap $9.3KP/E —$0.002$0.02
- ERNAWErnexa Therapeutics Inc. Warrants$0.0253▼ 9.96%Market cap $52.4KP/E —$0.0213$0.2278
- CINGWCingulate Inc. Warrants$0.01▲ 14.94%Market cap $133.3KP/E —$0.0026$0.12
- BFRIWBiofrontera Inc. Warrants$0.0052▼ 7.14%Market cap $357.2KP/E —$0.0052$0.1484
- BIVIWBioVie Inc. Warrant$0.2301▼ 7.96%Market cap $1.06MP/E —$0.13$0.79
- BDRXBiodexa Pharmaceuticals plc American Depositary Shs$0.456▲ 5.80%Market cap $1.10MP/E —$0.3371$44.7
- MTNBMatinas Biopharma Holdings Inc. Common Stock$2.37▼ 2.07%Market cap $1.72MP/E —$2.26$28.95
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CDTTW CDT Equity Inc. Warrant | $9.3K | — | $0.0074 | ▲ 21.31% | $0.002$0.02 |
| ERNAW Ernexa Therapeutics Inc. Warrants | $52.4K | — | $0.0253 | ▼ 9.96% | $0.0213$0.2278 |
| CINGW Cingulate Inc. Warrants | $133.3K | — | $0.01 | ▲ 14.94% | $0.0026$0.12 |
| BFRIW Biofrontera Inc. Warrants | $357.2K | — | $0.0052 | ▼ 7.14% | $0.0052$0.1484 |
| BIVIW BioVie Inc. Warrant | $1.06M | — | $0.2301 | ▼ 7.96% | $0.13$0.79 |
| BDRX Biodexa Pharmaceuticals plc American Depositary Shs | $1.10M | — | $0.456 | ▲ 5.80% | $0.3371$44.7 |
| MTNB Matinas Biopharma Holdings Inc. Common Stock | $1.72M | — | $2.37 | ▼ 2.07% | $2.26$28.95 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Institutional Ownership
March 31, 2026
- Total shares held
- 5.62M
- Total value held
- $1.32M
- Institutional holders
- 15
Top holders this quarter
- Unknown950.0K
- Unknown765.0K
- Unknown755.4K
- Unknown700.0K
- Unknown534.4K
- Unknown400.0K
- Unknown375.0K
- Unknown250.0K
- Unknown243.5K
- Unknown200.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
CDT Highlights Sarborg’s Quantum IP Expansion for Drug Discovery
CDT announced that Sarborg has added new quantum computing patents and is applying the technology to drug discovery. The move could broaden the company’s role in the pharmaceutical sector. The warrant is currently near the lower end of its 52‑week range and shows a moderate RSI, suggesting limited short‑term momentum. The high‑beta signal indicates that the price may still react strongly to market news.
CDT Highlights Sarborg’s Quantum IP Expansion for Drug Discovery. CDT announced that Sarborg has added new quantum computing patents and is applying the technology to drug discovery. The move could broaden the company’s role in the pharmaceutical sector. The warrant is currently near the lower end of its 52‑week range and shows a moderate RSI, suggesting limited short‑term momentum. The high‑beta signal indicates that the price may still react strongly to market news.